
David J. Moliterno, M.D.

General

Office Address

Department of Internal Medicine
University of Kentucky Medical Center
900 South Limestone Street
329 Charles T. Wethington Building
Lexington, KY 40536-0200
(859) 323-5843 voice
(859) 257-3537 fax
e-mail: Moliterno@uky.edu

Home Address

14 Scenic Court
Lancaster, KY 40444

Personal Data

Spouse: Judith Ann Moliterno, R.N., B.S.N.
Children: Nathaniel (25) and Benjamin (23)

Education

Undergraduate

College of Arts and Sciences
University of Michigan, Flint, Michigan
B.S. Honors, Biology, 8/1978-5/1982

Medical School

Medical College of Virginia
Virginia Commonwealth University, Richmond, Virginia
Doctor of Medicine, 8/1983-5/1987

Post Doctoral Training

Internship

Vanderbilt University Hospitals
Vanderbilt University Medical Center, Nashville, Tennessee
Intern in Internal Medicine, 7/1987-6/1988

Residency

Vanderbilt University Hospitals &
Nashville Veterans Affairs Medical Center
Vanderbilt University Medical Center, Nashville, Tennessee
Junior and Senior Resident in Internal Medicine, 7/1988-6/1990

185. Hernandez AV, Westerhout CM, Ioannidis JPA, Styerberg EW, Bueno H, White H, Theroux P, **Moliterno DJ**, Armstrong PW, Califf RM, Topol EJ, Wallentin LC, Simoons ML, Boersma E. Effects of platelet glycoprotein IIb/IIIa inhibitors in non-ST-segment-elevation acute coronary syndromes: Benefits and harm in different age subgroups. *Heart* 2007;93:450-455. PMID: 17065179
186. Kalyanasundaram A, Blankenship JC, Berger P, Herrmann H, McClure R, **Moliterno DJ**. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (Do Tirofiban and ReoPro® Give Similar Efficacy?) trial. *Catheterization and Cardiovascular Interventions* 2007;69:623-629. PMID: 17192960
187. Mardikar HM, Hiremath MS, **Moliterno DJ**, Mathew R, Arora R, Deo D, Hiremath JS, Deshpande NV, Khan A, Joseph J, and Mukherjee D. Optimal platelet inhibition in patients undergoing PCI: Data from the Multi-center Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR-PCI) Study. *American Heart Journal* 2007;154:344.e1-5. PMID: 17643586
188. **Moliterno DJ**. Editorial: The challenge of qualifying exceedingly rare occurrences—we can only see what we see. *Catheterization and Cardiovascular Interventions* 2007;69:719-720. PMID: 17390302
189. **Moliterno DJ**. Editorial: Restenosis following thin-strut bare-metal stents versus thick-strut drug-eluting stents. *Catheterization and Cardiovascular Interventions* 2007;69:799-800. PMID: 17377984
190. **Moliterno DJ**, Campbell CL. Editorial: Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag. *Journal of the American College of Cardiology* 2007;49:2318-2319. PMID: 17572246
191. Mukherjee D, **Moliterno DJ**. The timely coupling of mechanical revascularization following thrombolysis for myocardial infarction. *Cardiology* 2007;107:337-339 PMID: 17268199
192. Shishehbor MH, Lauer MS, Singh IM, Chew DP, Karha J, Brener SJ, **Moliterno DJ**, Ellis SG, Topol EJ, Bhatt DL. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? *Journal of the American College of Cardiology* 2007;49:849-854. PMID: 17320742
193. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, **Moliterno DJ**, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. *American Journal of Gastroenterology* 2008 103:2890-2907. PMID: 18853965 | *Circulation* 2008;52:1502-17. PMID 19017521
194. Brener SJ, **Moliterno DJ**, Aylward PE, van't Hof AWJ, Ruzyllo W, O'Neill WW, Hamm CW, Westerhout CM, Granger CB, Armstrong PW for the APEX-AMI Investigators. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. *European Heart Journal* 2008; 29:1127-1135. PMID: 18375399

195. Hamdalla H, **Moliterno DJ**. Editorial: Late drug-eluting stent thrombosis of unprotected left main coronary artery lesions—sometimes possible but rarely definite or probable. *European Heart Journal* 2008. PMID: 18664463
196. **Moliterno DJ**. Advances in antiplatelet therapy for ACS and PCI. *Journal of Interventional Cardiology* 2008;21:S18-24. PMID: 19090933
197. **Moliterno DJ**. Editorial: Late target lesion revascularization following drug-eluting stents—looking back and forward to success. *Catheterization and Cardiovascular Interventions* 2008;71:304-305. PMID: 18288752
198. **Moliterno DJ**. Late percutaneous recanalization of totally occluded infarct-related arteries—more than about time. *Catheterization and Cardiovascular Interventions* 2008;71:782-783. PMID: 18415953
199. **Moliterno DJ**. Racial differences in outcome following percutaneous coronary intervention. *Catheterization and Cardiovascular Interventions* 2008;72:45-46. PMID: n/a
200. **Moliterno DJ**, Ziada KM. Editorial: The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide. *Journal of the American College of Cardiology* 2008;51:536-537. PMID: 18237681
201. Mukherjee D, **Moliterno DJ**. Effectiveness of drug-eluting stents in real-world patients. *Journal of the American Medical Association* 2008;299:454-455. PMID: 1823075
202. Novaro GM, Asher CR, Bhatt DL, **Moliterno DJ**, Harrington RA, Lincoff AM, Newby LK, Tcheng JE, Hsu AP, Pinski SL. Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus Whites. *American Journal of Cardiology* 2008;101:506-509. PMID: 18312767
203. Oliveira GBF, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, **Moliterno DJ**, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Ohman M, Granger CB for the CATCH Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. *Archives of Internal Medicine* 2008;168:94-102. PMID: 18195201
204. Salah AK, Ahmed A, Bodiwala KN, Manaloor EJ, Thornton JW, **Moliterno DJ**. Cardiac amyloidosis. *Canadian Journal of Cardiology* 2008;24(5):e35. PMID: 18464954
205. Salah A, **Moliterno DJ**, Humphries R, Syed MA. Role of cardiac computed tomography and magnetic resonance imaging in the evaluation of acute chest pain in the emergency department. *International Journal of Cardiovascular Imaging* 2008;24:331-342. PMID: 17849234
206. Abdel-Latif A, **Moliterno DJ**. Antiplatelet polypharmacy in primary percutaneous coronary intervention: trying to understand when more is better. *Circulation* 2009;119:3168-3170. PMID: 19528332
207. Abdel-Latif A, **Moliterno DJ**. Prasugrel versus clopidogrel in primary PCI: considerations of the TRITON-TIMI 38 substudy. *Current Cardiology Reports* 2009;11:323-324. PMID: 19709491

208. Becker RC, **Moliterno DJ**, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA; TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomized, double-blind, placebo-controlled phase II study. *The Lancet* 2009;373:919-928. PMID: 19286091
209. Brener SJ, Westerhout CM, Fu Y, Todaro TG, **Moliterno DJ**, Wagner GS, Granger CB, Armstrong PW; APEX-AMI Investigators. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. *American Heart Journal* 2009;158:755-760. PMID: 19853693
210. Crespo EM, Oliveira GB, Honeycutt EF, Becker RC, Berger PB, **Moliterno DJ**, Anstrom KJ, Abrams CS, Kleiman NS, Moll S, Rice L, Rodgers JE, Steinhubl SR, Tapson VF, Granger CB, Ohman EM; CATCH Registry Investigators. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. *American Heart Journal* 2009;157:651-657. PMID: 19332191
211. Holmes DR Jr, Kereiakes DJ, Kleiman NS, **Moliterno DJ**, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. *Journal of the American College of Cardiology* 2009;54:95-109. PMID: 19573725
212. Jolicoeur EM, Ohman EM, Honeycutt E, Becker RC, Crespo EM, Oliveira GBF, **Moliterno DJ**, Anstrom KJ, and Granger CB. Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. *American Journal of Cardiology* 2009;104:292-297. PMID: 19576363
213. Koul S, **Moliterno DJ**. Editorial: Bare-metal versus drug-eluting stent placement among patients presenting with anemia. *Journal of the American College of Cardiology* 2009;2:337-338. PMID: 19463446
214. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, **Moliterno DJ**, Nassif D, Lopez JJ, Saucedo JF; on behalf of the EVENT Investigators. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry. *Journal of the American College of Cardiology* 2009;2:37-45. PMID: 19463396
215. Lopes RD, Ohman EM, Granger CB, Honeycutt EF, Anstrom KJ, Berger PB, Crespo EM, Oliveira GB, Moll S, **Moliterno DJ**, Abrams CS, Becker RC. Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation: The Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry. *American Journal of Cardiology* 2009;104:1285-1291. PMID: 19840578

216. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Lindner JR, **Moliterno DJ**, Mukherjee D, Pohost GM, Rosenson RS, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation* 2009;119:2250-2294. PMID: 19332472
217. **Moliterno DJ**. Left main and multivessel coronary artery stenting for patients deemed inoperable—a real need for a tandem approach. *Catheterization and Cardiovascular Interventions* 2009;74:311-312. PMID: 19642179
218. **Moliterno DJ**. Trifurcation left main coronary artery percutaneous revascularization—pushing catheters and envelopes. *Catheterization and Cardiovascular Interventions* 2009;73:32-33. PMID: 19089933
219. Mukherjee D, **Moliterno DJ**. Effectiveness of PCI for non-acute coronary artery disease. *The Lancet* 2009;373:870-872. PMID: 19286067
220. Mukherjee D, **Moliterno DJ**. Second-generation drug-eluting stents and the continuous need for rapidly available real world data. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2009;2:1236-1239. PMID: 20129550
221. Rajan L, **Moliterno DJ**. Editorial: Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention. *European Heart Journal* 2009;30:1687-1689. PMID: 19429914
222. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, **Moliterno DJ**, French PA, Steinhubl SR, Becker RC; 2008 Platelet Colloquium Participants. G-protein-coupled receptors as signaling targets for antiplatelet therapy. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2009;29:449-457. PMID: 19023091
223. Wang TY, Zhang M, Fu Y, Armstrong PW, Newby LK, Gibson CM, **Moliterno DJ**, Van de Werf F, White HD, Harrington RA, Roe MT. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) undergoing diagnostic angiography. *American Heart Journal* 2009;157:716-723. PMID: 19332201
224. Abdel-Latif A, **Moliterno DJ**. Editorial: Protein C and S Deficiency as a Risk Factor for Stent Thrombosis—When a Rare Disorder Can Predispose to Rare Events. *Journal of Interventional Cardiology* 2010;23:565-568. PMID: 20796164

225. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF, Harrington RA, Bates ER, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Hlatky MA, Jacobs AK, Kaul S, **Moliterno DJ**, Weitz HH, Wesley DJ. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. *Journal of the American College of Cardiology* 2010;56:2051-2066. PMID: 21126648
 226. George JC, **Moliterno DJ**, Dangas GD. American College of Cardiology Annual Scientific Session 2010: update in interventional cardiology *Journal of the American College of Cardiology: Cardiovascular Interventions* 2010;3:562-564. PMID: 20488415
 227. Holmes DR Jr, Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG, Williams DO, Kimura T, **Moliterno DJ**. Stent thrombosis. *Journal American College of Cardiology* 2010;56:1357-1365. PMID: 20946992
 228. Means RT Jr, **Moliterno DJ**, Allison GR, Perman JA, Lofgren RP, Karpf M, Debeer FC. The evolution of a department of internal medicine under an integrated clinical enterprise model: the University of Kentucky experience. *Academic Medicine* 2010;85:531-537. PMID: 20182134
 229. **Moliterno DJ**. Rotational atherectomy for resistant chronic total occlusions: another spin for tough old problems. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2010;76:372-373. PMID: 20839350
 230. Tackett AH, Bailey AL, Foody JM, Miller JM, Apperson-Hansen C, Ohman EM, Hochman JS, Karnash SL, Califf RM, Topol EJ, **Moliterno DJ**. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. *American Heart Journal* 2010;160:678-684. PMID: 20934562
 231. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AWJ, Campo G, Hamm C, Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, **Moliterno DJ**, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. *European Heart Journal* 2010;31:35-49. PMID: 19755402
 232. Wiisanen ME, **Moliterno DJ**. The use of single versus dual antiplatelet therapy beyond 1 year following drug-eluting stent implantation. *Current Cardiology Reports* 2010;12:357-360. PMID: 20544309
 233. Anaya P, **Moliterno DJ**. Patient, Heal Thyself: The Ongoing Evolution of Patient Self-directed Care and Hand-Held Technology. *Annals of Internal Medicine* 2011;154:500-501. PMID: 21464353
 234. Elayi CS, Whitbeck MG, Charnigo R, Shah J, Macaulay TE, Morales G, Gurley JC, Kakavand B, Thal S, Ching CK, Khaykin Y, Verma A, Barrett C, Bai R, Di Biase L, Patwardhan A, **Moliterno DJ**, Natale A. Is there an Association Between External Cardioversions and Long Term Mortality and Morbidity - Insights from the AFFIRM Study. *Circulation, Arrhythmia and Electrophysiology* 2011;4:465-469. PMID: 21511994
 235. **Moliterno DJ**. ACP Journal Club: Increased doses of clopidogrel or aspirin did not prevent cardiovascular events. *Annals of Internal Medicine* 2011;154:JC1-7. PMID: 21242361
-

236. **Moliterno DJ**. Unfractionated versus low-molecular-weight heparin for primary angioplasty – More data suggesting to go low. *Catheterization and Cardiovascular Interventions* 2011;77:191-192. PMID: 21290553
237. **Moliterno DJ**, TENACITY Steering Committee and Investigators. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. *Catheterization and Cardiovascular Interventions* 2011;77:1001-1009. PMID: 21598351
238. Elayi CS, Allen CL, Leung S, Lusher S, Morales GX, Wiisanen M, Aikat S, Kakavand B, Shah JS, **Moliterno DJ**, Gurley JC. Inside-out access: a new method of lead placement for patients with central venous occlusions. *Heart Rhythm*. 2011;8:851-857. PMID: 21237290
239. Rajan L, **Moliterno DJ**. Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS? *Current Cardiology Reports* 2011. PMID: 21607650
240. Ziada KM, Charnigo R, **Moliterno DJ**. Long-term follow-up of drug-eluting stents placed in the setting of ST-segment elevation myocardial infarction. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2011;4:39-41. PMID: 21251627
241. Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Thérroux P, Stone GW, **Moliterno DJ**, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA. Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials. *Circulation: Cardiovascular Quality and Outcomes*. 2011;4:448-458. PMID: 21712522
242. Wallace EL, **Moliterno DJ**. The Use of Drug-Eluting Stents Versus Bypass Surgery for Left Main Coronary Artery Disease. *Current Cardiology Reports* 2011. PMID: 21735107
243. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner TJ, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, **Moliterno DJ**, Mukherjee D, Rosenson RS, Stein JH, Weitz HH, Wesley DJ. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration With the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. *Journal of the American Society of Hypertension*. 2011;5:259-352. PMID: 21771565

244. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, **Moliterno DJ**, Becker RC, Angiolillo DJ. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. *Thrombosis and Haemostasis* 2011;106. PMID: 21785808
245. Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, **Moliterno DJ**, Becker RC, Angiolillo DJ. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a north american perspective: executive summary. *Circulation: Cardiovascular Interventions* 2011;4:522-534. PMID: 22010191
246. Tricoci P, Huang Z, Held C, **Moliterno DJ**, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; the TRACER Investigators. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. *New England Journal of Medicine* 2012;366:20-33. PMID: 22077816
247. Kristensen SD, Würtz M, Grove EL, De Caterina R, Huber K, **Moliterno DJ**, Neumann FJ. Contemporary Use of Glycoprotein IIb/IIIa Inhibitors. *Thrombosis and Haemostasis* 2012;107:215-224. PMID: 22234385
248. Wallace EL, Abdel-Latif A, Charnigo R, **Moliterno DJ**, Brodie B, Matnani R, Ziada KM. Meta-Analysis of Long-Term Outcomes for Drug-Eluting Stents Versus Bare-Metal Stents in Primary Percutaneous Coronary Interventions for ST-Segment Elevation Myocardial Infarction. *American Journal of Cardiology* 2012;109:932-940. PMID: 22221949
249. Abdel-Latif A, **Moliterno DJ**. Creating biodegradable-polymer drug-eluting stents: shortening the duration of polymer and dual antiplatelet therapy while lengthening the follow-up. *Catheterization and Cardiovascular Interventions* 2012;79:217-218. PMID: 22271552
250. Holmes DR, Mack MJ, Kaul S, Agnihotri A, Kappetein AP, Alexander KP, Linderbaum JA, Bailey SR, Mukherjee C, Calhoon JH, Mukherjee D, Carabello BA, Otto CM, Desai MY, Ruiz CE, Edwards FH, Sacco RL, Francis GS, Smith D, Gardner TJ, Thomas JD, Harrington RA, Bhatt DL, Ferrari VA, Hernandez AF, Fisher JD, Jacobs AK, Garcia MJ, Kaul S, Gardner TJ, Linderbaum JA, Gentile F, **Moliterno DJ**, Gilson MF, Weitz HH. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: Developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Catheterization and Cardiovascular Interventions* 2012;79:1023-1082 PMID: 22294439
251. van Diepen S, Roe MT, Lopes RD, Stebbins A, James S, Newby LK, **Moliterno DJ**, Neumann FJ, Ezekowitz JA, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Theroux P, Granger CB. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. *Journal of Thrombosis and Thrombolysis* 2012;34:106-113. PMID: 22307842

252. Chan MY, Sun JL, Newby LK, Lokhnygina Y, White HD, **Moliterno DJ**, Thérroux P, Ohman EM, Simoons ML, Mahaffey KW, Pieper KS, Giugliano RP, Armstrong PW, Califf RM, Van de Werf F, Harrington RA. Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. *International Journal of Cardiology* 2012;167:548-554. PMID: 22341697
 253. Foley JD 3rd, **Moliterno DJ**. Contemporary occurrence of stent thrombosis in clinical practice: better never than late. *Catheterization and Cardiovascular Interventions* 2012;79:557-558. PMID: 22344988
 254. Bashore TM, Balter S, Barac A, Byrne JG, Cavendish JJ, Chambers CE, Hermiller JB Jr, Kinlay S, Landzberg JS, Laskey WK, McKay CR, Miller JM, **Moliterno DJ**, Moore JW, Oliver-McNeil SM, Popma JJ, Tommaso CL. 2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions Expert Consensus Document on Cardiac Catheterization Laboratory Standards Update: a Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *Journal of the American College of Cardiology* 2012;59:2221-2305. PMID: 22575325
 255. Bashore TM, Balter S, Barac A, Byrne JG, Cavendish JJ, Chambers CE, Hermiller JB Jr, Kinlay S, Landzberg JS, Laskey WK, McKay CR, Miller JM, **Moliterno DJ**, Moore JW, Oliver-McNeil SM, Popma JJ, Tommaso AC, Harrington RA, Bates ER, Bhatt DL, Bridges CR, Eisenberg MJ, Ferrari VA, Fisher JD, Gardner T, Gentile F, Gilson MF, Hlatky MA, Jacobs AK, Kaul S, Moliterno DJ, Mukherjee D, Rosenson RS, Weitz HH, Wesley DJ. 2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions Expert Consensus Document on Cardiac Catheterization Laboratory Standards Update: American College of Cardiology Foundation Task Force on Expert Consensus Documents Society of Thoracic Surgeons Society for Vascular Medicine. *Catheterization and Cardiovascular Interventions* 2012;80:E37-49. PMID: 22570114
 256. Rajan L, **Moliterno DJ**. New anticoagulants in ischemic heart disease. *Current Cardiology Reports* 2012;14:450-456. PMID: 22528556
 257. Wiisanen ME, **Moliterno DJ**. Platelet protease-activated receptor antagonism in cardiovascular medicine. *Coronary Artery Disease* 2012;23:375-379. PMID: 22781741
 258. Capodanno D, Bhatt DL, Goto S, O'Donoghue ML, **Moliterno DJ**, Tamburino C, Angiolillo DJ. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. *Journal of Thrombosis and Haemostasis*. 2012;10:2006-2015. PMID: 22845871
 259. Anaya P, **Moliterno DJ**. CT Angiography for Emergency Decision Making in Acute Coronary Syndromes: Applying Future Vision Now. *Current Cardiology Reports* 2012;14:537-539. PMID: 22890753
 260. Dunn SP, Holmes DR Jr, **Moliterno DJ**. Drug-drug interactions in cardiovascular catheterizations and interventions. *Journal of the American College of Cardiology: Cardiovascular Interventions* 2012;5:1195-1208. PMID: 23257367
 261. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, Jondeau G, Natale A, Roy D, Smyth S, **Moliterno DJ**, Elayi CS. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. *European Heart Journal* 2012;34:1481-1488. PMID: 23186806
-

262. Kalra N, **Moliterno DJ**. Zotarolimus-eluting stents among patients with renal impairment undergoing percutaneous coronary intervention. *Catheterizations Cardiovascular Interventions* 2012;80:893-894. PMID: 23166098
263. El Mallah W, **Moliterno DJ**. Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement. *Catheterizations Cardiovascular Interventions* 2012;80:406-407. PMID: 22933348
264. Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoun JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD, Harrington RA, Bhatt DL, Ferrari VA, Fisher JD, Garcia MJ, Gardner TJ, Gentile F, Gilson MF, Hernandez AF, Jacobs AK, Kaul S, Linderbaum JA, **Moliterno DJ**, Weitz HH. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Journal of Thoracic and Cardiovascular Surgery* 2012;144:e29-84. PMID: 22898522
265. van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, Roe MT, Ezekowitz JA, **Moliterno DJ**, Neumann FJ, Reist C, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Granger CB, Theroux P; on behalf of the APEX AMI Investigators. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. *International Journal of Cardiology* 2013;S0167-5273:00019-3. PMID: 23394896
266. Leonardi S, Tricoci P, White HD, Armstrong PW, Huang Z, Wallentin L, Aylward PE, **Moliterno DJ**, Van de Werf F, Chen E, Providencia L, Nordrehaug JE, Held C, Strony J, Rorick TL, Harrington RA, Mahaffey KW. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) trial. *European Heart Journal* 2013;34:1723-1731. PMID: 23530022
267. Abdel-Latif A, **Moliterno DJ**. Remote ischemic preconditioning in elective percutaneous coronary intervention does not protect myocardium nor mobilize endothelial progenitor cells. *Catheterizations Cardiovascular Interventions* 2013;81:937-938. PMID: 23606488
268. **Moliterno DJ**, Smyth SS. Tissue necrosis factor α and targeting its receptor in ischaemic heart disease. *Heart* 2013;99:1305-1306. PMID: 23697653
269. Rajan L, **Moliterno DJ**. Stent thrombosis through the generations. *The Journal of Invasive Cardiology* 2013;25:337-338. PMID: 23813061
270. Campbell CL, **Moliterno DJ**. The Value of High-Sensitivity Troponin in Assessing the Extent of Benefit Provided by Ticagrelor versus Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndromes. *Circulation* 2013;129:278-280. PMID: 24170389
271. Anaya P, **Moliterno DJ**. The evolving role of cardiac troponin in the evaluation of cardiac disorders. *Current Cardiology Reports* 2013;15:420. PMID: 24057774

272. Whellan DJ, Tricoci P, Chen E, Huang Z, Leibowitz D, Vranckx P, Marhefka GD, Held C, Nicolau JC, Storey RF, Ruzyllo W, Huber K, Sinnaeve P, Weiss AT, Dery JP, **Moliterno DJ**, de Werf FV, Aylward PE, White HD, Armstrong PW, Wallentin L, Strony J, Harrington RA, Mahaffey KW. Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery: Subgroup Analysis from the TRACER Trial. *Journal of the American College of Cardiology* 2014;63:1048-1057. PMID: 24211500
273. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, **Moliterno DJ**, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet* 2013;382:1714-1722. PMID: 24004642
274. Whitbeck MG, Charnigo RJ, Shah J, Morales G, Leung SW, Fornwalt B, Bailey AL, Ziada K, Sorrell VL, Zegarra MM, Thompson J, Hosn NA, Campbell CL, Gurley J, Anaya P, Booth DC, Biase LD, Natale A, Smyth S, **Moliterno DJ**, Elayi CS; the AFFIRM investigators. QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study. *Europace* 2014;16:803-811. PMID: 24368753
275. Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, **Moliterno DJ**, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial). *American Journal of Cardiology* 2014;113:936-944. PMID: 24444781
276. Storey RF, Kotha J, Smyth S, **Moliterno DJ**, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. *Thrombosis and Haemostasis* 2014;111:883-891. PMID: 24402559
277. Held C, Tricoci P, Huang Z, Van de Werf F, White HD, Armstrong PW, Ambrosio G, Aylward PE, **Moliterno DJ**, Wallentin L, Chen E, Erkan A, Jiang L, Strony J, Harrington RA, Mahaffey KW. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. *European Heart Journal Acute Cardiovascular Care*. 2014;3:246-256. PMID: 24627331
278. Ruiz-Rodriguez E, **Moliterno DJ**. High-risk coronary anatomy versus high-risk physiology as outcome predictors in acute coronary syndromes. *Catheterization Cardiovascular Interventions*. 2014;83:684-685. PMID: 24638944
279. Judge HM, Jennings LK, **Moliterno DJ**, Hord E, Ecob R, Tricoci P, Rorick T, Kotha J, Storey RF. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. *Platelets*. 2015;26:236-242. PMID: 24750101
280. Bhatt DL, Hulot JS, **Moliterno DJ**, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. *Circulation Research* 2014;114:1929-43. PMID: 24902976
-

281. Ziada K, **Moliterno DJ**. Revascularization for patients with stable coronary artery disease. *British Medical Journal* 2014;23:348. PMID: 24958028
282. White HD, Huang Z, Tricoci P, Van de Werf F, Wallentin L, Lokhnygina Y, **Moliterno DJ**, Aylward PE, Mahaffey KW, Armstrong PW. Reduction in overall occurrences of ischemic events with vorapaxar: results from Tracer. *Journal of the American Heart Association* 2014;3:e001032. PMID: 25012288
283. Randall MH, **Moliterno DJ**. The impact of left anterior descending coronary artery length on survival following myocardial infarction: the apex and beyond. *Catheterization Cardiovascular Interventions* 2014;84:321-322. PMID: 25045098
284. Valgimigli M, Tricoci P, Huang Z, Aylward PE, Armstrong PW, Van de Werf F, Leonardi S, White HD, Widimsky P, Harrington RA, Cequier A, Chen E, Lokhnygina Y, Wallentin L, Strony J, Mahaffey KW, **Moliterno DJ**. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from TRACER Trail). *American Journal of Cardiology* 2015;114:665-673. PMID: 25129064
285. Jones WS, Tricoci P, Huang Z, **Moliterno DJ**, Harrington RA, Sinnaeve PR, Strony J, Van de Werf F, White HD, Held C, Armstrong PW, Aylward PE, Chen E, Patel MR, Mahaffey KW. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). *American Heart Journal* 2014;168:588-596. PMID: 25262270
286. Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, Wallentin L, Held C, Aylward PE, **Moliterno DJ**, Jennings LK, White HD, Armstrong PW, Harrington RA, Strony J, Mahaffey KW. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. *American Heart Journal* 2014;168:869-877. PMID: 25458650
287. Campbell CL, **Moliterno DJ**. Potential hazards of adding nonsteroidal anti-inflammatory drugs to antithrombotic therapy after myocardial infarction: time for more than a gut check. *Journal of the American Medical Association* 2015;313:801-802. PMID: 25710655
288. Cornel JH, Tricoci P, Lokhnygina Y, **Moliterno DJ**, Wallentin L, Armstrong PW, Aylward PE, Clare RM, Chen E, Leonardi S, Van de Werf F, White HD, Held C, Strony J, Mahaffey KW, Harrington RA. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). *American Journal of Cardiology* 2015; 115:1325-1332. PMID: 25776457
289. Abdel-Latif A, **Moliterno DJ**. Bifurcation stenting techniques and outcomes in patients with stable coronary artery disease: more evidence suggesting simpler is safer. *JACC Cardiovascular Interventions* 2015;8:561-563. PMID: 25907083
290. Kragholm K, Halim SA, Yang Q, Schulte PJ, Hochman JS, Melloni C, Mahaffey KW, **Moliterno DJ**, Harrington RA, White HD, Armstrong PW, Ohman EM, Van de Werf F, Tricoci P, Alexander JH, Giugliano RP, Newby LK. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. *Circulation Cardiovascular Quality Outcomes* 2015;8:357-367. PMID: 26152683

291. Ziada KM, Abdel-Latif A, Charnigo R, **Moliterno DJ**. Safety of an abbreviated duration of dual antiplatelet therapy (≤ 6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials. *Catheterization Cardiovascular Interventions* 2016;87:722-732. PMID: 26309050
292. Kim SM, **Moliterno DJ**. Ageless benefits of transradial access for percutaneous coronary revascularization. *Catheterization Cardiovascular Interventions* 2015;86:973-974. PMID: 26541798
293. van Diepen S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F, Strony J, Wallentin L, **Moliterno DJ**, White HD, Mahaffey KW, Harrington RA, Armstrong PW. Efficacy and safety of vorapaxar in non-ST-segment elevation acute coronary syndrome patients undergoing noncardiac surgery. *Journal of the American Heart Association* 2015;4. PMID: 26672080
294. Déry JP, Mahaffey KW, Tricoci P, White HD, Podder M, Westerhout CM, **Moliterno DJ**, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV. Arterial access and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. *Catheterization Cardiovascular Interventions* 2016;88:163-173. PMID: 26698636
295. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, **Moliterno DJ**, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. *Journal of the American College of Cardiology* 2016;67:2224-2234. PMID: 27079334
296. Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, **Moliterno DJ**, Wallentin L, Held C, Aylward PE, Cornel JH, Bode C, Huber K, Nicolau JC, Ruzylo W, Harrington RA, Tricoci P. Validation of BARC bleeding criteria in patients with acute coronary syndromes: the TRACER trial. *Journal of the American College of Cardiology* 2016;67:2135-2144. PMID: 27151345
297. Popma CJ, Sheng S, Korjian S, Daaboul Y, Chi G, Tricoci P, Huang Z, **Moliterno DJ**, White HD, Van de Werf F, Harrington RA, Wallentin L, Held C, Armstrong PW, Aylward PE, Strony J, Mahaffey KW, Gibson CM. Lack of concordance between local investigators, angiographic core laboratory, and clinical event committee in the assessment of stent thrombosis: results from the TRACER angiographic substudy. *Circulation Cardiovascular Interventions* 2016. PMID: 27162212
298. Baber U, Dangas G, Chandrasekhar J, Sartori S, Steg PG, Cohen DJ, Giustino G, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, **Moliterno DJ**, Weisz G, Colombo A, Pocock S, Mehran R. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. *JACC Cardiovascular Interventions* 2016;9:1349-57. PMID: 27388822
299. Yu J, Baber U, Mastoris I, Dangas G, Sartori S, Steg PG, Cohen DJ, Giustino G, Chandrasekhar J, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, **Moliterno DJ**, Colombo A, Pocock S, Mehran R. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. *JACC Cardiovascular Interventions* 2016;9:1461-9. PMID: 27478113
-

300. Åkerblom A, Clare RM, Lokhnygina Y, Wallentin L, Held C, Van de Werf F, **Moliterno DJ**, Patel UD, Leonardi S, Armstrong PW, Harrington RA, White HD, Aylward PE, Mahaffey KW, Tricoci P. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. *American Heart Journal*. 2016;178:1-8. PMID: 27502846
301. Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, **Moliterno DJ**, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, Lopes RD. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. *American Heart Journal* 2016;178:176-84. PMID: 27502866
302. Hess PL, Wojdyla DM, Al-Khatib SM, Lokhnygina Y, Wallentin L, Armstrong PW, Roe MT, Ohman EM, Harrington RA, Alexander JH, White HD, Van de Werf F, Piccini JP, Held C, Aylward PE, **Moliterno DJ**, Mahaffey KW, Tricoci P. Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. *JAMA Cardiology* 2016;1:73-79. PMID: 27437658
303. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, **Moliterno DJ**, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. *Circulation: Cardiovascular Interventions* 2016;9 Review. PMID: 27803042
304. Harskamp RE, Clare RM, Ambrosio G, Held C, Lokhnygina Y, **Moliterno DJ**, White HD, Aylward PE, Armstrong PW, Mahaffey KW, Harrington RA, Van de Werf F, Wallentin L, Strony J, Tricoci P. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. *European Journal of Acute Cardiovascular Care* 2017;6:155-163. PMID: 26895973
305. Chandrasekhar J, Bansilal S, Baber U, Sartori S, Aquino M, Farhan S, Vogel B, Faggioni M, Giustino G, Ariti C, Colombo A, Chieffo A, Kini A, Saporito R, Michael Gibson C, Witzenbichler B, Cohen D, **Moliterno DJ**, Stuckey T, Henry T, Pocock S, Dangas G, Gabriel Steg P, Mehran R. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. *Catheterization Cardiovascular Interventions* 2017;88:E217-E225. PMID: 27650638
306. **Moliterno DJ**. Research Correspondence: One Good Point, One Great Figure (or Table). *JACC Cardiovascular Interventions* 2017;10:2347-2348. PMID: 29169508
307. **Moliterno DJ**, Ziada KM. More Time to SORT OUT Clinical Outcomes After First-Generation Drug-Eluting Stents: Related Versus Unrelated Events. *Journal of the American College of Cardiology* 2017;69:625-627. PMID: 28183506
308. Faggioni M, Baber U, Sartori S, Giustino G, Cohen DJ, Henry TD, Farhan S, Ariti C, Dangas G, Gibson M, Giacoppo D, Krucoff MW, Aquino M, Chandrasekhar J, **Moliterno DJ**, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. *JACC Cardiovascular Interventions* 2017;10:645-654. PMID: 28330641

309. Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, **Moliterno DJ**, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. *European Heart Journal* 2017;38:804-810. PMID: 28363222
310. Koshizaka M, Lopes RD, Newby LK, Clare RM, Schulte PJ, Tricoci P, Mahaffey KW, Ogawa H, **Moliterno DJ**, Giugliano RP, Huber K, James S, Harrington RA, Alexander JH. Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. *American Journal of Medicine* 2017;130:1170-1176. PMID: 28396226
311. **Moliterno DJ**. A Letter to the (Founding) Editor: A King by Any Name. *JACC Cardiovascular Interventions* 2017;10:1378-1379. PMID: 28683945
312. **Moliterno DJ**. JACC: Cardiovascular Interventions 2.0: The Journey Begins. *JACC Cardiovascular Interventions* 2017;10:1473-1474. PMID: 28728666
313. **Moliterno DJ**. The Value of Focus. *JACC Cardiovascular Interventions* 2017;10:1603-1604. PMID: 28797442
314. **Moliterno DJ**. Be Careful What You Read and the Company You Keep. *JACC Cardiovascular Interventions* 2017;10:1715-1716. PMID: 28838484
315. **Moliterno DJ**. Little Kids, Little Problems-Big Kids, Big Problems. *JACC Cardiovascular Interventions* 2017;10:1807-1808. PMID: 28882289
316. Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, **Moliterno DJ**, Colombo A, Mehran R. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). *Circulation: Cardiovascular Interventions* 2017;10:9. PMID: 28916600
317. Schoos M, Chandrasekhar J, Baber U, Bhasin A, Sartori S, Aquino M, Vogel B, Farhan S, Sorrentino S, Kini A, Kruckoff M, **Moliterno DJ**, Henry TD, Weisz G, Gibson CM, Iakovou I, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen D, Stuckey T, Ariti C, Dangas G, Pocock S, Mehran R. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). *American Journal Cardiology* 2017;120:904-910. PMID: 28778417
318. **Moliterno DJ**. One Man's Vacation, Another Man's Stress Test. *JACC Cardiovascular Interventions* 2017;10:2133-2134. PMID: 29050634
319. **Moliterno DJ**. CTO-Chronic Total Occlusions and Continuous Training Opportunity. *JACC Cardiovascular Interventions* 2017;10:2231-2232. PMID: 29122138

320. **Moliterno DJ.** The Year of Special Anniversaries: Tin, Crystal, Silver and Ruby. *JACC Cardiovascular Interventions* 2017;10:2587-2588. PMID: 29268892
321. Guimarães PO, Leonardi S, Huang Z, Wallentin L, Van de Werf F, Aylward PE, Held C, Harrington RA, **Moliterno DJ**, Armstrong PW, White HD, Alexander KP, Lopes RD, Mahaffey KW, Tricoci P, Clinical Features and Outcomes of Patients with Type 2 Myocardial Infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) Trial. *American Heart Journal* 2018;196:28-35. PMID: 29421012
322. Misumida N, **Moliterno DJ.** Hybrid coronary revascularization: Time for a new comparator? *Catheter Cardiovascular Interventions* 2018;91:213-214. PMID: 29405596
323. **Moliterno DJ.** The Top Papers of 2017: By Subsequent Citations and Online Views and Downloads. *JACC Cardiovascular Interventions* 2018;11:325-327. PMID: 29413251
324. **Moliterno DJ.** The Top Papers of 2017: Editor's Pick. *JACC Cardiovascular Interventions* 2018;11:513-515. PMID: 29519391
325. **Moliterno DJ.** State-of-the-Art Papers: Gemstones. *JACC Cardiovascular Interventions* 2018;11:613-614. PMID: 29566810
326. Rymer JA, Tempelhof MW, Clare RM, Pieper KS, Granger CB, Van de Werf F, **Moliterno DJ**, Harrington RA, White HD, Armstrong PW, Lopes RD, Mahaffey KW, Newby LK. Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. *American Heart Journal* 2018;201:103-110. PMID: 29910048
327. Baber U, Li SX, Pinnelas R, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dargas G, Aquino MB, Sartori S, Chieffo A, **Moliterno DJ**, Colombo A, Mehran R. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). *Circulation Cardiovascular Interventions* 2018;11:e006144. PMID: 29870385
328. **Moliterno DJ.** Images in Intervention: Icons. *JACC Cardiovascular Interventions* 2018;11:1018-1019. PMID: 29798769
329. Tricoci P, Newby LK, Clare RM, Leonardi S, Gibson CM, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, **Moliterno DJ**, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. *JACC Cardiovascular Interventions*.2018;11:856-864. PMID: 29747915
330. Tricoci P, Neely M, Whitley MJ, Edelstein LC, Simon LM, Shaw C, Fortina P, **Moliterno DJ**, Armstrong PW, Aylward P, White H, Van de Werf F, Jennings LK, Wallentin L, Held C, Harrington RA, Mahaffey KW, Bray PF. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. *Blood Cells Molecules and Diseases* 2018;72:37-43. PMID: 30055940

331. **Moliterno DJ.** Year 1: A Short Look Back and a Long Look Forward. *JACC Cardiovascular Interventions* 2018;1:1793-1795. PMID: 30190073
332. Ungar L, Clare RM, Rodriguez F, Kolls BJ, Armstrong PW, Aylward P, Held C, **Moliterno DJ**, Strony J, Van de Werf F, Wallentin L, White HD, Tricoci P, Harrington RA, Mahaffey KW, Melloni C. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. *Journal of the American Heart Association* 2018;7:e009609. PMID: 30526198
333. **Moliterno DJ.** Being a Great Reviewer: Remembering the “Why”. *JACC Cardiovascular Interventions* 2018;11:2130-2131. PMID: 30336820
334. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, **Moliterno DJ**, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. *Circulation.* 2018;138:527-536. PMID:30571525
335. Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD, Farhan S, Sharma M, Ariti C, Dangas G, Gibson M, Faggioni M, Krucoff MW, Aquino M, Chandrasekhar J, **Moliterno DJ**, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). *American Journal of Cardiology* 2018;122:1638-1646. PMID: 30270177
336. Schoos M, Power D, Baber U, Sartori S, Claessen B, Camaj A, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Cohen D, Antoniucci D, Krucoff M, Hermiller J, Gibson C, Chieffo A, **Moliterno D**, Colombo A, Pocock S, Dangas G, Mehran R. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. *American Journal of Cardiology.* 2019;1;123(5):709-716. PMID:30612724
337. Moalem K, Baber U, Chandrasekhar J, Claessen BE, Sartori S, Aquino M, Dangas G, Iakovou I, Colombo A, Kini A, Gibson M, Krucoff M, Chieffo A, **Moliterno D**, Witzenbichler B, Pocock S, Mehran R. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. *Clinical Research Cardiology.* 2019;3 [Epub ahead of print] PMID: 30607496
338. Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, **Moliterno D**, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. *Circulation Cardiovascular Quality and Outcomes.* 2019;12:e004945. PMID:30606052
339. **Moliterno DJ**, Windecker S. Mitral Regurgitation and Evolving Transcatheter Treatments: Insights From the JACC Family of Journals. *Journal of the American College of Cardiology* 2019;73:1353-1357. PMID:30898211
340. Faggioni M, Baber U, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Claessen BE, Dangas GD, Gibson CM, Krucoff MW, Vogel B, **Moliterno DJ**, Sorrentino S, Colombo A, Chieffo A, Kini A, Farhan S, Ariti C, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous

- Coronary Intervention. *Circulation Cardiovascular Interventions* 2019;12(4):e007133. PMID: 30998384
341. Joyce LC, Baber U, Claessen BE, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Ariti C, Dangas G, Faggioni M, Aoi S, Gibson CM, Aquino M, Krucoff MW, Vogel B, **Moliterno DJ**, Sorrentino S, Colombo A, Chieffo A, Kini A, Guedeney P, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. *JACC Cardiovascular Interventions* 2019;27;12(10):983-992. PMID: 31122354
 342. Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, **Moliterno DJ**, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. *JACC Cardiovascular Interventions* 2019;26;12(16):1521-1537. PMID: 31202949
 343. Ziada KM, **Moliterno DJ**. Dual Antiplatelet Therapy: Is It Time to Cut the Cord With Aspirin? *Journal of the American Medical Association* 2019;25;321(24):2409-2411. PMID: 31237621
 344. Vogel B, Chandrasekhar J, Baber U, Mastoris I, Sartori S, Aquino M, Krucoff MW, Moliterno DJ, Henry TD, Weisz G, Gibson CM, Iakovou I, Kini AS, Farhan S, Sorrentino S, Faggioni M, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen DJ, Stuckey T, Ariti C, Dangas GD, Pocock S, Mehran R. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. *Journal of Thrombosis and Haemostasis* 2019;19(10):1704-1711. PMID: 31365942
 345. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Džavík V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, **Moliterno D**, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. *New England Journal of Medicine* 2019;21;381(21):2032-2042. PMID: 31556978

Publications- Peer-Reviewed: Silent Authorship

1. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. *New England Journal of Medicine* 1997;337:1118-1123. PMID: 9340503
2. The Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) Investigators. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade. *Lancet* 1998;352:87-92. PMID: 9672272
3. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. *Journal of the American College of Cardiology* 1998;32:2003-2010. PMID: 9857885

4. The NICE 4 Investigators. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 Trials. *Journal of Invasive Cardiology* 2000;12:E14-E18. PMID: 11156724
5. The Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. *Circulation* 2000;101:2788-2794. PMID: 10859283
6. The SYMPHONY Investigators. Comparison of sibrافiban with aspirin, or both for secondary prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrافiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY). *Lancet* 2000;355:337-345. PMID: 10665552
7. The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrافiban, or both for secondary prevention after acute coronary syndromes. *Circulation* 2001;103:1727-1733. PMID: 11282902
8. The NICE 4 Investigators. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. *Journal of Invasive Cardiology* 2001;13:272-278. PMID: 11287711
9. The PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. *Circulation* 2002;105:316-321. PMID: 11804986
10. The PRIME Investigators. Multi-center, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion In Myocardial Infarction Evolution (PRIME) Trial. *American Heart Journal* 2002;143:95-105. PMID: 11773918
11. The APEX-AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. *Journal of the American Medical Association* 2007;297:43-51. PMID: 17200474
12. Cannon CP; STRIVE Scientific Committee. Updated Strategies and therapies for reducing ischemic and vascular events (STRIVE) unstable angina/non-ST-elevation myocardial infarction critical pathway toolkit. *Critical Pathways in Cardiology* 2008;7:43-81. PMID: 18458666
13. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *Journal of the American Medical Association* 2008;299:1903-1913. PMID: 18430909
14. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E; TRA2°P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 Trial. *American Heart Journal* 2009;158:335-341.e3. PMID: 19699854
15. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) Trial: study design and rationale. *American Heart Journal* 2009;158:327-334.e4. PMID: 19699853

16. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *Journal of the American College of Cardiology*. 2010;55:2614-2662. PMID: 20513610
17. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS, ACCF/ACRA/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation task force on expert consensus documents. *Journal of the American College of Cardiology* 2010;55:2663-2699. PMID: 20513611
18. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK, ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation task force on consensus documents. *Circulation* 2010;121:2462-2508. PMID: 20479157
19. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS, ACCF/ACRA/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation task force on expert consensus documents. *Circulation*. 2010;121:2509-2543. PMID: 20479158
20. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forcica MA, Frishman WH, Jaigobin C, Kostis JB, Mancina G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation*. 2011;123:2434-2506. PMID: 21518977
21. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. *The New England Journal of Medicine* 2012;366:1404-1413. PMID: 22443427
22. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial. Third universal definition of myocardial infarction. *European Heart Journal* 2012;33:2551-2567. PMID: 22922414

Publications – Web Sites

1. Tan WS, **Moliterno DJ**. Acute coronary syndromes: unstable angina in non-Q wave MI. www.healthstream.com
2. **Moliterno DJ**. Contributing author to ACC Cardio. www.acc.org
3. **Moliterno DJ**. Acute Reactions from the AHA, 2003. www.atherothrombosis.org
4. **Moliterno DJ**. Knowing (and applying) our ABCs—online commentary of Mukherjee D, et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. *Circulation* 2004;109:745-9. www.americanheart.org
5. **Moliterno DJ**. Platelet GP IIb/IIIa Inhibitors. www.interventionalfellowsinstitute.com
6. **Moliterno DJ**. Thrombosis. Chapter 24 in “ACCSAP-6” (Adult Clinical Cardiology Self-Assessment Program) edited by Lewis RP; co-edited by O’Gara P, Friesinger II GC, Hirsch GA; American College of Cardiology, 2007. www.cardiosource.com
7. **Moliterno DJ**, Sketch M, Popma, Mukherjee D. Chief Editor and author or co-author of 6 modules in: “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program), published by American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions. www.cardiosource.com

Publications - Book Chapters

1. **Moliterno DJ**, Elliott JM, Topol EJ. Randomized trials of myocardial revascularization. In “Current Problems in Cardiology” edited by O'Rourke RA; Mosby-Year Book, Inc., Mar 1995;20(3):123-190. PMID: 7600846
2. **Moliterno DJ**, Topol EJ. Clinical evaluation of restenosis. Chapter 93 in “Atherosclerosis and Coronary Artery Disease” edited by Fuster V, Ross R, Topol EJ; Raven Press, New York, 1995, pp 1505-1526.
3. **Moliterno DJ**, Topol EJ. Restenosis following coronary intervention. Update 17 for “Textbook of Interventional Cardiology” edited by Topol EJ; W.B. Saunders Company, Philadelphia, 1995, pp 257-2722.
4. Nissen SE, Tuzcu EM, De Franco AC, **Moliterno DJ**. Evaluation of stenosis severity: quantitative angiography, coronary flow reserve, and intravascular ultrasound. In “Strategic Approaches in Coronary Intervention” edited by Ellis SG, Holmes DA. Williams & Wilkins, Baltimore, 1995, pp 207-234.
5. **Moliterno DJ**, Topol EJ. Percutaneous versus surgical coronary revascularization. A summary of the RITA, CABRI, GABI, EAST, and BARI Trials. Update 23 for “Textbook of Interventional Cardiology” edited by Topol EJ; W. B. Saunders Company, Philadelphia, 1996, pp 335-344.
6. **Moliterno DJ**, Topol EJ. Thrombolysis in acute myocardial infarction. In “Cardiovascular Drug Therapy” edited by Mezznerli FH; W. B. Saunders Company, Philadelphia, 1996, pp 1430-1442.
7. Nissen SE, Tuzcu EM, De Franco AC, **Moliterno DJ**. Intravascular ultrasound assessments in coronary interventions. In “Handbook of Cardiovascular Interventions” edited by Sigwart U; Churchill Livingstone, New York, 1996.
8. Granger CJ, **Moliterno DJ**. Bedside anticoagulant testing. In “Acute Coronary Syndromes” edited by Topol EJ; Marcel Dekker, New York, 1998, pp 385-403.
9. Miller JM, Ohman EM, **Moliterno DJ**, Califf RM. Clinical evaluation of restenosis. In “Textbook of Interventional Cardiology” 3rd ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 1998, pp 379-415.
10. **Moliterno DJ**, Cohen M. Unstable angina. In “Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology” edited by Verstraete M, Fuster V, Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 439-460.
11. **Moliterno DJ**, Granger CB. Differences between unstable angina and myocardial infarction: the pathophysiologic and clinical spectrum. In “Acute Coronary Syndromes” edited by Topol EJ; Marcel Dekker, New York, 1998, pp 67-103.
12. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In “Comprehensive Cardiovascular Medicine” edited by Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 2397-2432.
13. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In “Textbook of Cardiovascular Medicine” edited by Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 2065-2100.

14. Steinhubl SR, **Moliterno DJ**. Antiplatelet and anticoagulant therapy in the prevention of ischemic heart disease. In "Preventative Cardiology" edited by Robinson R; Futura Publishing Co. Inc., Armonk, NY, 1998, pp 355-382.
15. **Moliterno DJ**. Anticoagulants in the treatment of acute coronary syndromes. In "Textbook of Interventional Cardiology" 3rd ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 1999, pp 25-51.
16. **Moliterno DJ**, White HD. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In "Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease" edited by Lincoff AM, Topol EJ. Humana Press, Inc., Totowa, New Jersey 1999, pp 201-227.
17. Granger CJ, **Moliterno DJ**. Bedside anticoagulant testing. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, 2000, pp 541-562.
18. Kapadia SR, **Moliterno DJ**. Section II editors: Chronic ischemic syndromes. In "Manual of Cardiovascular Medicine" edited by Marso SP, Griffin BP, Topol EJ; Lippincott Williams & Wilkins, New York, 2000, pp 69-96.
19. **Moliterno DJ**. Anticoagulants. In "CathSAP II" edited by Nissen SE; American College of Cardiology; Bethesda, 2000, pp 23-30.
20. **Moliterno DJ**. Care after myocardial infarction. Section in "Conn's Current Therapy 2000" edited by RE Rakel; W.B. Saunders Co., Philadelphia, 2000, pp 328-333.
21. **Moliterno DJ**, Granger CB. Differences between unstable angina and myocardial infarction: The Pathophysiologic and Clinical Spectrum. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, NY, 2000, pp 135-172.
22. Mukherjee DB, **Moliterno DJ**. Bedside platelet monitoring. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, 2000, pp 563-597.
23. Chan AW, **Moliterno DJ**. Restenosis: the clinical issues. In "Textbook of Interventional Cardiology" 4th ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 2002, pp 415-453.
24. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In "Textbook of Cardiovascular Medicine" 2nd ed. edited by Topol EJ; Williams & Wilkins Publishers, Philadelphia, 2002, pp 1715-1750.
25. **Moliterno DJ**. Anticoagulants and their use in acute coronary syndromes and coronary interventions. In "Textbook of Interventional Cardiology" 4th ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 2003, pp 33-64.
26. **Moliterno DJ**. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In "Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease" 2nd ed. edited by Lincoff AM, Topol EJ. Humana Press Inc., Totowa, NJ, 2003, pp 233-262.
27. Chan AW, **Moliterno DJ**. Clinical evaluation of restenosis. In "Atherothrombosis and Coronary Artery Disease" 2nd ed. edited Fuster V, Topol EJ, Nabel EG; Raven Press, New York, 2004.

28. Quinn MJ, **Moliterno DJ**. Anticoagulation trials in acute coronary syndromes. In “A Comprehensive Handheld-Based Approach to CardioVascular Medicine” edited by Roffi M, Meier B, Topol, EJ; CVMstat[®], Handheldmed, Inc., Little Rock, AR, 2004.
29. Mukherjee D, **Moliterno DJ**. Bedside platelet monitoring. In “Acute Coronary Syndromes” 3rd ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 481-506.
30. Mukherjee D, **Moliterno DJ**. Monitoring anticoagulants in the catheterization laboratory and in the ICU when using combination therapies. In “Clinical, Interventional, and Investigational Thrombocardiology (Fundamental and Clinical Cardiology)” edited by Becker RC, Harrington RA, Marcel Dekker Publications, 2005.
31. Saw J, **Moliterno DJ**. Antiplatelet agents. In “Platelet Function: Assessment, Diagnosis and Treatment” edited by Quinn MJ, Fitzgerald D; Humana Press, Inc., Totowa, NJ, 2005, pp 335-367.
32. Saw J, **Moliterno DJ**. Bedside anticoagulant testing. In “Acute Coronary Syndromes” 3rd ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 457-480.
33. Saw J, **Moliterno DJ**. Differences between unstable angina and acute myocardial infarction: pathophysiologic and clinical spectrum. In “Acute Coronary Syndromes” 3rd ed. edited by Topol EJ; Marcel Dekker, New York, 2005, pp 129-156.
34. Saw J, **Moliterno DJ**. The rebirth of interest in pharmacoinvasive therapy in the stent era. In “Pharmacoinvasive Therapy in Acute Myocardial Infarction” edited by Sobel B, Dauerman H; Taylor & Francis, New York, 2005, pp 131-148.
35. Brown B, **Moliterno DJ**. Glycoprotein IIb/IIIa inhibitors – status 2005. In “Therapeutic Strategies in Thrombosis” edited by Kristensen SD, De Caterina R, **Moliterno DJ**; Clinical Publishing, Oxford, 2006, pp 37-60.
36. Hamdalla H, **Moliterno DJ**. Procedures and management: multivessel angioplasty. Chapter 14 in “SCAI Interventional Cardiology Board Review Book” edited by Kern M, et al. Lippincott Williams & Wilkins, 2006, pp 147-156.
37. Marshall JJ, **Moliterno DJ**. Pharmacology and ionotropes, antiarrhythmics, sedatives, and lipid-lowering agents. Chapter 6 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, 2006, pp 41-48.
38. **Moliterno DJ**. Antiplatelet, antithrombotic, and thrombolytic agents. Chapter 5 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, 2006, pp 32-40.
39. **Moliterno DJ**, Cho L, Mukherjee D. Primary, rescue, and facilitated angioplasty. Chapter 11 in “900 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Philadelphia, 2006, pp 88-96.
40. Morrison DA, **Moliterno DJ**, Vetrovec GW. Approach to coronary artery disease: medical therapy (including risk-factor modification), coronary artery bypass graft surgery, and percutaneous coronary intervention including complex PCI. Chapter 19 in “SCAI Interventional Cardiology Board Review Book” edited by Kern M, et al. Lippincott Williams & Wilkins, 2006, pp 189-201.

41. Saraff K, Mukherjee D, **Moliterno DJ**. Monitoring of antithrombotic drugs. In “Therapeutic Strategies in Thrombosis” edited by Kristensen SD, et al. Clinical Publishing, Oxford, 2006, pp 359-383.
42. **Moliterno DJ**. Thrombosis. Chapter 24 in “ACCSAP-6” (Adult Clinical Cardiology Self-Assessment Program) edited by Lewis RP, co-edited by O’Gara P, Friesinger II GC, Hirsch GA; American College of Cardiology, 2007. www.cardiosource.com
43. Bhatheja R, **Moliterno DJ**. The interrelationship of thrombin and platelets—the protease-activated Receptor-1. Chapter 30 in “New Therapeutic Agents in Thrombosis and Thrombolysis” edited by Freedman JE, Loscalzo J; Informa Healthcare, USA, 2008, pp 517-533.
44. Falluji N, **Moliterno DJ**. Restenosis and in-stent restenosis. In “Essential Interventional Cardiology” 2nd ed. edited by Norell MS, Perrins EJ, Meier B, Lincoff AM; Saunders, Philadelphia, 2008, pp 151-161.
45. Hamdalla H, **Moliterno DJ**. Multivessel coronary artery disease. Chapter 9.5 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
46. Jozic J, **Moliterno DJ**. Platelet glycoprotein IIb/IIIa receptor antagonists: fundamental and pharmacological aspects. Chapter 12 in “Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease” edited by Angiolillo DJ, Kastrati A, Simon DI; Informa Healthcare, USA, 2008, pp 101-105.
47. Macaulay T, **Moliterno DJ**. Vasopressors, ionotropes, and vasodilators. Chapter 6.8 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
48. **Moliterno DJ**. Platelet glycoprotein IIb/IIIa inhibitors. Chapter 6.2 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
49. **Moliterno DJ**. Restenosis. Chapter 2.6 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
50. Mukherjee D, **Moliterno DJ**. Chronic total Occlusions. Chapter 9.1 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
51. Mukherjee D, **Moliterno DJ**. Heparin-induced thrombocytopenia. Chapter 2.5 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.

52. Mukherjee D, **Moliterno DJ**. Hypercoaguable disorders. Chapter 2.4 in “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, 2008.
53. Dawson CB, Mukherjee D, **Moliterno DJ**. High dose tirofiban. Chapter 19 in “Pharmacology in the Catheterization Laboratory” edited by Waksman R, Ajani A; Blackwell Publishing, Oxford, 2009, pp 154-157.
54. Falluji N, **Moliterno DJ**, Mukherjee D. Rescue coronary intervention for failed thrombolysis. Chapter 7 in “Primary Angioplasty in Acute Myocardial Infarction” edited by Tchong, JE; Humana Press, Inc., Totowa, New Jersey, 2009, pp 101-114.
55. Dosh KM, **Moliterno DJ**. Glycoprotein IIb/IIIa Inhibitors. Chapter 8 in “Mechanical Reperfusion for STEMI: From Randomized Trial to Clinical Practice” edited by DeLuca G, Lansky A; Informa Healthcare USA, New York, New York, 2009, pp 83-93.
56. Macaulay TE, **Moliterno DJ**. Vasopressors, vasodilators, and antithrombotics in the catheterization laboratory. Chapter 7 in “Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease” edited by Mukherjee D, Bates E, Roffi M, **Moliterno DJ**; Informa Healthcare, London, 2010, pp 53-66.
57. Gurley J, **Moliterno DJ**. Radiation Safety, Equipment, and Basic Concepts. Chapter 3 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 23-37.
58. **Moliterno DJ**, Macaulay TE. Antiplatelet, Antithrombotic, and Thrombolytic Agents. Chapter 5 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 50-59.
59. Dunn SP, **Moliterno DJ**. Antiarrhythmics, Sedatives, and Lipid-lowering Agents. Chapter 7 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, **Moliterno DJ**; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 69-76.
60. Macaulay TE, Moliterno DJ. Inotropes, Vasopressors, and Vasodilators. Chapter 8 in “Interventional Cardiology 1001 Questions: An Interventional Cardiology Board Review” edited by Mukherjee D, Cho L, Moliterno DJ; Lippincott Williams & Wilkins, Baltimore, MD, 2012, pp 77-84.
61. Foley JD 3rd, **Moliterno DJ**. Platelet ADP P2Y12 Inhibitors: Thienopyridines, Chapter 3 in “Therapeutic Advances in Thrombosis, 2nd edition” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 26-46.
62. Foley JD 3rd, **Moliterno DJ**. Platelet ADP P2Y12 Inhibitors: Nonthienopyridines, Chapter 4 in 7 “Therapeutic Advances in Thrombosis, 2nd edition.” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 47-61.

63. Wiisanen ME, **Moliterno DJ**. Interrelationship of Thrombin and Platelets: The Protease Activated Receptor-1. Chapter 7 in “Therapeutic Advances in Thrombosis, 2nd edition.” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 71-86.
64. **Moliterno DJ**. Hemostasis, Platelet Biology, and the Coagulation Cascade. Chapter 1.3 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
65. Anaya P, **Moliterno DJ**. Hypercoaguable Disorders. Chapter 2.4 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
66. **Moliterno DJ**. Heparin-Induced Thrombocytopenia. Chapter 6.6 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
67. Macaulay TE, **Moliterno DJ**. Vasopressors, vasodilators, and antithrombotics in the catheterization laboratory. Chapter 7 in “Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease” edited by Mukherjee D, Bates E, Roffi M, Lange RA, **Moliterno DJ**; Informa Healthcare, London, 2018, pp 71-88.
68. **Moliterno DJ**, Macaulay TE. Antiplatelet, Antithrombotic, and Thrombolytic Agents. Chapter 5 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 23-36.
69. Dunn SP, **Moliterno DJ**. Antiarrhythmics, Sedatives, and Lipid-lowering Agents. Chapter 7 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 68-75.
70. Macaulay TE, Moliterno DJ. Inotropes, Vasopressors, and Vasodilators. Chapter 8 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 76-83.

Publications - Textbook Editor

1. Kristensen SD, De Caterina R, **Moliterno DJ**. Therapeutic Strategies in Thrombosis. Clinical Publishing, Oxford, 2005.
2. Mukherjee D, Cho L, **Moliterno DJ**. 900 Questions: An Interventional Cardiology Board Review. Lippincott Williams & Wilkins, Philadelphia, 2006.
3. **Moliterno DJ**. Editor-in-chief of CathSAP-3 (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program). American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, Washington, DC, 2008.
4. Mukherjee D, Bates ER, Roffi M, **Moliterno DJ**. Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease. Informa Healthcare, USA, London, 2010.
5. Mukherjee D, Cho L, **Moliterno DJ**. 1001 Questions: An Interventional Cardiology Board Review. Lippincott Williams & Wilkins, Baltimore, 2012.
6. **Moliterno DJ**, Kristensen SD, De Caterina R. Therapeutic Advances in Thrombosis, 2nd Edition. Wiley-Blackwell, London, 2012.
7. **Moliterno DJ**. Editor-in-chief of CathSAP-4 (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program). American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions, Washington, DC, 2012.
8. Mukherjee D, Bates ER, Roffi M, Lange RA, **Moliterno DJ**. Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease, 2nd Edition. Informa Healthcare, USA, London, 2018.
9. Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Interventional Cardiology. 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition. Wolters Kluwer, New York, 2019.